Maxcure Nutravedics Limited - Due diligence report

A 360° intelligence report on Akums: trust score, financial health, credit view, compliance, directors, growth and distress signals - genera…

1994-02-10 Delhi, Delhi Active Unlisted Active Compliant
Connect MCP
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Akums — 360° Intelligence Report

Generated from MCA filings & public records
89/100
Trust Score
Low Risk

Akums is assessed as Low Risk with a Trust Score of 89/100. Akums is an active public limited indian non-government company incorporated in 1994, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.

Report generated on 21 Nov 2026 from the latest processed filings. Maxcure Nutravedics Limited snapshot & full profile →

Overall Assessment CautionWeakNeutralGoodStrong Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
89/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
74/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
85/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 0 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 85/100 Low Risk
  • Moderate gearing (D/E 38%).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.
  • Externally credit-rated (AA-).

Charges position: 4 open ( 48.0 cr ) · 5 satisfied ( 12.5 cr ).

Banking relationships (from registered charges)
LenderChargesAmount
Citi Bank N.A.1 48.0 cr
Yes Bank Limited1 48.0 cr
Icici Bank Limited2 48.0 cr
Others2 48.0 cr
The Hongkong And Shanghai Banking Corporation Limited1 48.0 cr
Standard Chartered Bank1 48.0 cr
Compliance Score: 74/100 Moderate
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2025).
  • Litigation present in 2 court forum(s).
  • 4 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
KHYALI DUTT SHARMA 01234567 Director 01/04/2018 6 yrs Approved
GEETANJALI SHARMA 01234567 Director 01/04/2018 6 yrs Approved
Geetanjali Malhotra 01234567 Director 01/04/2018 6 yrs Approved
PARVEEN SONI 01234567 Director 01/04/2018 6 yrs Approved
NIDHI SHARMA 01234567 Director 01/04/2018 6 yrs Approved
Geetanjali Sharma 01234567 Director 01/04/2018 6 yrs Approved
  • 6 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2025 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
AKUMS DRUGS AND PHARMACEUTICALS LIMITED
Subsidiaries
-
Group entities
-
Capital events
0 allotment(s) · 2 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
AKUMS DRUGS AND PHARMACEUTICALS LIMITED Holding Company 74.00%
MEDIBOX PHARMA PRIVATE LIMITED Subsidiary Company 74.00%

Key managerial personnel: KHYALI DUTT SHARMA (Whole-time director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 75 · Distress 90
Growth signals & trust indicators
Profit expanded 1.42 year-on-year.
Asset base grew 2.1x - capacity expansion.
Net margin improved to 24%.
EPFO headcount growing - hiring signal.
Operating for 32+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
4 open charge(s) registered - assets are encumbered.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence83/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment85/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 4 open charge(s) already registered.
  • Compliance record supports lending.
Investor view86/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 4 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
15 Jun 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
23 Apr 2024
Charge satisfied
Standard Chartered Bank
16 Apr 2024
Charge created
The Hongkong And Shanghai Banking Corporation Limited - 25.00 cr
16 Feb 2024
Charge satisfied
Others
31 Jul 2023
Charge satisfied
Others
17 Sep 2022
Director appointed
GEETANJALI SHARMA (Company Secretary)
Director appointed
Geetanjali Malhotra (Company Secretary)
Director appointed
Geetanjali Sharma (Company Secretary)
04 Apr 2022
Charge created
Standard Chartered Bank - 20.00 cr
04 Jan 2022
Charge created
Hdfc Bank Limited - 20.00 cr
09 Nov 2021
Charge created
Others - 4.00 cr
18 Sep 2021
Charge created
Yes Bank Limited - 49.00 cr
24 Mar 2021
Director ceased
ROHITASWA
13 Sep 2020
Director ceased
PARVEEN SONI
10

Key Observations

Auto-generated from the data above
Revenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - manageable leverage.
Net worth is positive.
6 active director(s) / partner(s); board looks stable and experienced.
4 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of AA- from Icra.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Approximately 199 employees on EPFO payroll records.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Ankura Hospital U85191TG2011PTC077997 Hyderabad, Telangana, India
Mumbai Oncocare Center U74999MH2017PTC301138 Borivali West, Maharashtra, India
Akumentis U72900DL2010PLC206414 Delhi, Delhi, India
Dragarwal L85110TN1994PLC027366 Chennai, Tamil Nadu, India
Jeena Sikho Lifecare L52601PB2017PLC046545 Zirakpur, Punjab, India
Krsnaa Diagnostics L74900PN2010PLC138068 Pune, Maharashtra, India
Nephroplus L85100TG2009PLC066359 Shaikpet, Telangana, India
Rhealthtrust U74899HR1990PLC054770 Gurgaon, Haryana, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Akums before audits and certifications: compliance score 74/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Akums: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 85/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Akums - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 89/100, distress signals and MSME payment-delay disclosures - know whether Akums pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Akums - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Akums an active company?

Akums has MCA status “Active” with a compliance score of 74/100 (Moderate).

Is Akums financially healthy?

Akums has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Akums?

Its overall Trust Score is 89/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Akums?

The ultimate holding entity is AKUMS DRUGS AND PHARMACEUTICALS LIMITED. 6 active director(s) are on record.

Does Akums have loans or charges against its assets?

4 open charge(s) are registered against its assets, and 5 earlier charge(s) stand satisfied.

Is Akums up to date with its ROC filings?

Balance sheet slightly behind (Mar 2025). Overall compliance score: 74/100 (Moderate).

Is it risky to lend to Akums?

Its Credit Risk Score is 85/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.